QuidelOrtho Corporation (NASDAQ: QDEL) is a Healthcare company (Medical - Specialties) with a market capitalization of $677M. The Maz Rating grades it against the other companies in its sector.
QuidelOrtho Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $9.87, QuidelOrtho Corporation trades at 0.3x sales and 0.4x book value, with an EV/EBITDA of 11.1. Over the last twelve months it generated about $2.6B of revenue and a net loss of $370M. It runs a gross margin of 44.2%, an operating margin of -4.7% and a net margin of -14.2%. It shows return on equity of -20.1%, return on invested capital of -2.4% and a free cash flow yield of -17.4%. On the balance sheet: a debt-to-equity ratio of 1.74 and a current ratio of 1.36. Over the past 52 weeks the share price ranged from $9.82 to $35.58, with a beta of 0.68.
QuidelOrtho Corporation does not currently pay a dividend.
15 Wall Street analyst ratings cover the stock: 6 Buy, 7 Hold and 2 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, QuidelOrtho Corporation (QDEL) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 338.6% / 30% · (Cash+Inv) / Mkt Cap (36m) 29.6% / 30% · Interest income / Revenue 0.00% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 338.6% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 22.1% / 33% · Receivables / Mkt Cap (36m) 51.2% / 49% · Interest income / Revenue 0.00% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 338.6% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 22.1% / 33.33% · Receivables / Mkt Cap (24m) 51.2% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 48.9% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 2.87% / 33.33% · Receivables / Avg Assets (4Q) 7.93% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
| FTSE | Debt / Total Assets 50.8% / 33.33% · (Cash+ST Inv) / Total Assets 3.32% / 33.33% · (Cash+Recv) / Total Assets 11.0% / 33.33% · Interest income / Revenue 0.00% / 5% | Fail |
No. As of September 2026, QuidelOrtho Corporation (QDEL) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. QuidelOrtho Corporation is over the AAOIFI limit on Debt / Mkt Cap (36m).
QuidelOrtho Corporation reported no interest income in the latest quarter, so there is nothing to purify from its dividend on that basis.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 27, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.